# GRN1005 for Brain Metastases From Breast or Lung Cancer

> **NCT01679743** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Breast Cancer
- Lung Neoplasms
- Breast Neoplasms
- Lung Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** GRN 1005

## Key facts

- **NCT ID:** NCT01679743
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-08-29
- **Primary completion:** 2014-08-11
- **Final completion:** 2014-08-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679743, "GRN1005 for Brain Metastases From Breast or Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01679743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*